QIAGEN N.V. (NYSE: QGEN, Frankfurt Stock Exchange: QIA) and BD (Becton, Dickinson and Company) (NYSE: BDX) announced today that they have reached a settlement in the patent infringement lawsuit related
Q3 2021: Net sales rise 11% (+10% constant exchange rates, CER) to $535 million and adjusted diluted EPS unchanged at $0.58 ($0.58 CER) from Q3 2020, both well above outlook Non-COVID
Easy-to-use cartridge receives CE-marking in Europe and will launch soon Syndromic test differentiates between influenza A and B, RSV and SARS-CoV-2, a critical test for upcoming flu seasons
Relocation expands QIAGEN's global knowledge hub for diagnostics development City has been base of company's pioneering role in Precision Medicine for a decade CityLabs 2.0 facility
QIAGEN leverages QuantiFERON-TB technology to advance global efforts against TB TB IGRA testing now accessible in high burden, low resource and decentralized settings Study data also